deltatrials
Completed OBSERVATIONAL NCT05350202

Emp-Activity: Empagliflozin Functional Capacity

Empagliflozin Functional Capacity - Non-Interventional Study

Sponsor: Boehringer Ingelheim

Conditions Heart Failure
Interventions Empagliflozin
Updated 25 times since 2022 Last updated: Aug 21, 2025 Started: Dec 18, 2022 Primary completion: Jul 25, 2024 Completion: Jul 25, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05350202, this observational or N/A phase trial focuses on Heart Failure and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 25 times since 2022, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

25 versions recorded
  1. Feb 2026 — Present [monthly]

    Completed

  2. Sep 2025 — Feb 2026 [monthly]

    Completed

  3. Jan 2025 — Sep 2025 [monthly]

    Completed

  4. Oct 2024 — Jan 2025 [monthly]

    Completed

    Status: Active Not RecruitingCompleted

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting

Show 20 earlier versions
  1. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  2. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting

  3. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting

  4. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting

    Status: RecruitingActive Not Recruiting

  5. Dec 2023 — Feb 2024 [monthly]

    Recruiting

  6. Oct 2023 — Dec 2023 [monthly]

    Recruiting

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting

  11. May 2023 — Jun 2023 [monthly]

    Recruiting

  12. Apr 2023 — May 2023 [monthly]

    Recruiting

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting

  14. Feb 2023 — Mar 2023 [monthly]

    Recruiting

    Status: Not Yet RecruitingRecruiting

  15. Dec 2022 — Feb 2023 [monthly]

    Not Yet Recruiting

  16. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting

  17. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting

  18. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting

  19. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting

  20. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .